340B Drug Pricing Program
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take 鈥渋mmediate enforcement action,鈥 including鈥
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take 鈥渋mmediate enforcement action,鈥 including鈥
AHA letter regarding the Health Resources and Services Administration鈥檚 response to Johnson & Johnson鈥檚 (J&J) most recent attempt to undermine the 340B Drug Pricing Program.
J&J announces major change to 340B pricing; HRSA responds to preemptive AHA advocacy.
Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto.
The Health Resources and Services Administration Aug. 7 requested public comment on how petitioners file initial claims in the 340B Administrative Dispute Resolution process and how it affects stakeholders鈥 administrative load.
Trinity Health Grand Rapids 鈥 anchored by a 283-bed hospital 鈥 operates two freestanding emergency departments, two urgent care clinics, three public health centers, a large HIV clinic and 57 outpatient clinics.
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission鈥檚 2024-2025 cycle.
AHA comments on MedPAC topics to be considered in the new cycle: the 340B Drug Pricing Program, inpatient rehabilitation facility (IRF) payments, the physician fee schedule (PFS) and telehealth.
As the annual 340B hospital recertification period approaches, the Health Resources and Services Administration鈥檚 Office of Pharmacy Affairs is hosting a certification webinar on Wednesday, Aug. 7 from 1-2 p.m. ET.